Description

Vinblastine Sulphate for Injection

Healthy Inc is a specialized global supplier and exporter of high-potency antineoplastic and oncology therapies. We provide high-purity Vinblastine Sulphate for Injection (10 mg), manufactured in WHO–GMP certified sterile cytotoxic facilities. This “Tubulin-Binding” specialist is a mandatory export to oncology centers, hematology wards, and government health ministries in Africa, LATAM, and Southeast Asia, serving as a foundational chemotherapeutic agent for curative regimens in Hodgkin’s lymphoma and advanced testicular cancer.

Product Overview

This formulation contains Vinblastine Sulphate, a highly potent, cell-cycle-specific antineoplastic drug derived from the Madagascar periwinkle plant (Catharanthus roseus).

The “Mitotic Spindle” Specialist:

• Mechanism (Microtubule Inhibition): Vinblastine specifically binds to microtubular proteins (tubulin) of the mitotic spindle. This binding halts the crystallization and polymerization of microtubules, paralyzing the cancer cell in the metaphase of cellular division and rapidly inducing apoptosis.
• Curative Regimen Backbone: It is indispensable in modern oncology. It is the “V” in the ABVD regimen (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) which is the gold-standard curative protocol for Hodgkin’s Lymphoma, and the “B” in the BEP regimen (Bleomycin, Etoposide, Platinum/Cisplatin) for metastatic testicular germ cell tumors.
• Toxicity Profile (Versus Vincristine): Unlike its sister drug Vincristine, Vinblastine’s dose-limiting toxicity is severe bone marrow suppression (leukopenia), while it produces significantly less neurotoxicity. This distinct profile dictates its specific clinical pairings.

Product Composition & Strength

We supply this product as a Sterile Lyophilized Powder (White to Off-White) or as a Ready-to-Use Liquid Solution in glass vials.

*Pack Sizes: Single Vial encased in specialized protective cytotoxic shrink-wrap.

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers and Oncology Distributors.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• HPAPI Isolation Technology: Manufactured within dedicated, negative-pressure cytotoxic isolator suites to guarantee zero cross-contamination and ensure maximum operator safety during the handling of this High-Potency Active Pharmaceutical Ingredient (HPAPI).
• Vesicant Safety Packaging: Because Vinblastine causes catastrophic tissue necrosis if spilled, our vials are manufactured with shatter-resistant bottom designs and clear protective overwrap to safeguard oncology nurses and pharmacists during admixture.

Therapeutic Indications (Human Use)

Indicated for use alone or in combination with other oncolytic drugs for:

• Hodgkin’s Lymphoma: A core component of the ABVD curative regimen.
• Testicular Cancer: Advanced germ cell tumors (component of the BEP regimen).
• Breast Cancer: Advanced or metastatic disease unresponsive to endocrine therapy.
• Kaposi’s Sarcoma: Palliative treatment.
• Histiocytosis X: Letterer-Siwe disease.

Dosage & Administration

Recommended Dosage (Strictly as per Medical Oncologist):

• Route: INTRAVENOUS (IV) USE ONLY.
• Standard Adult Dose: Dosing is highly individualized and titrated weekly based on white blood cell (WBC) counts. Typically begins at 3.7 mg/m² and may be increased cautiously. Absolute maximum single dose generally does not exceed 18.5 mg/m².
• Administration Technique: Administered strictly via a freely running intravenous infusion (Normal Saline or 5% Dextrose) via a central venous catheter or a newly established, secure peripheral IV to minimize extravasation risk. Injection should take approximately 1 minute.

Safety Warnings (CRITICAL):

• BLACK BOX WARNING (Fatal Intrathecal Error): FATAL IF GIVEN INTRATHECALLY. FOR INTRAVENOUS USE ONLY. Administration into the spinal fluid causes ascending paralysis, massive central nervous system destruction, and inevitable death. Syringes containing this product must be explicitly labeled with this warning.
• Myelosuppression: Profound leukopenia (white blood cell drop) is the dose-limiting toxicity. WBC counts must be checked prior to every dose. If the WBC falls below 4,000/mm³, the next dose should be withheld or reduced.
• Vesicant Hazard (Tissue Necrosis): Extravasation into surrounding tissue causes severe pain, phlebitis, and deep tissue necrosis. If extravasation occurs, stop the injection instantly, apply localized heat, and administer hyaluronidase per oncology protocol.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving the needs of international Pharma Traders, Wholesalers, and Bulk Drug Distributors. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Oncology and Cytotoxic Injectables, allowing brands to launch high-quality generic medicines under their own label. Whether you are looking for a reliable Hospital Tender Supplier for government procurement in Africa or a B2B Pharma Marketplace partner for Latin America, our logistics network ensures secure cold-chain delivery. We actively support Pharmaceutical Drop Shipping models and bulk indenting, ensuring that every Generic Medicine Wholesaler receives WHO-GMP certified products at competitive rates.